784155-54-0

Usage

Uses

Used in Pharmaceutical Synthesis:
N-(5-FLUORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE is utilized as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs due to its unique chemical structure and reactivity.
Used in Agrochemical Synthesis:
In the agrochemical industry, N-(5-FLUORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE is employed as a building block for the creation of agrochemicals, playing a role in the formulation of pesticides and other agricultural products to enhance crop protection and yield.
Used as a Reagent in Organic Chemistry:
N-(5-FLUORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE also serves as a reagent in various organic chemistry reactions, facilitating specific transformations and syntheses that are valuable in the preparation of complex organic molecules and materials.

InChI:InChI=1/C10H13FN2O/c1-10(2,3)9(14)13-8-5-4-7(11)6-12-8/h4-6H,1-3H3,(H,12,13,14)

Upstream product

• 3282-30-2 pivaloyl chloride 
• 21717-96-4 2-amino-5-fluoropyridine 
• 31301-51-6 2-chloro-5-fluoropyridine 

Downstream Products

• 1188433-81-9 N-(5-fluoro-3-formylpyridin-2-yl)-2,2-dimethylpropanamide 
• 1188433-88-6 2-amino-5-fluoropyridine-3-carbaldehyde 
• 1188431-89-1 2-(6-fluoro-2-trifluoromethyl-[1,8]-naphthyridine-3-carbonyl)cyclohexane-1,3-dione 
• 823218-50-4 N-(5-fluoro-3-iodo-pyridin-2-yl)-2,2-dimethyl-propionamide 

Relevant academic research and scientific papers

NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES

The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

Rhodium(III)-catalyzed oxidative olefination of pyridines and quinolines: Multigram-scale synthesis of naphthyridinones

A Rh(III)-catalyzed oxidative olefination of pyridines and quinolines has been achieved. This method has a broad substrate scope and has been applied to the expeditious, multigram-scale synthesis of naphthyridinones.

HERBICIDAL COMPOUNDS

The present invention relates to novel herbicidal oxopyridine and thionopyridine derivatives of Formula (I), or an agronomically acceptable salt of said compound wherein R1, R5, R6, R7, X1, X2/s

HERBICIDAL COUMPOUNDS

The present invention relates to novel herbicidal [l,8]-naphthyridines of Formula (Ia) or (Ib), or an agronomically acceptable salt of said compound wherein R2, R3, R4, R5,R6,R7, R8, n, m, X and Q are as defined herein. The invention further relates to processes and intermediates for the preparation of the [l,8]-naphthyridines, to compositions which comprise the herbicidal compounds, and to their use for controlling weeds, in particular in crops of useful plants.

HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I), (where variables R1, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

The present invention refers to chemical compounds of formula (I), as well as pharmaceutically acceptable salts, esters and produgs thereof, wherein R1 to R5 have the significance given in claim 1. They can be used for the preparation of medicaments.

CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula (I) and Formula (II) (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.